(RTTNews) – Novavax, Inc. (NVAX) shares rose nearly 6% on Friday morning after learning that the biotechnology company has begun a complex test of its COVID-19 vaccine.
NVAX has recently traded at $ 108. 33, up $ 5. 89 or 5. 75% on the Nasdaq.
On Thursday night, Novavax announced that it had presented its first Phase 3 to compare the efficacy, protection and immunogenicity of NVX-CoV2373, Novavax’s COVID-19 candidate vaccine. The trial is being conducted in the UK in partnership with the UK government vaccine. Working Group.
The company plans to register and vaccinate up to 10,000 more people between the ages of 18 and 84.
NVX-CoV2373 is a candidate vaccine designed from the SARS-CoV-2 genetic series, the virus guilty of COVID-19 disease. NVX-CoV2373 was created by generating recombinant Novavax nanoparticles to generate a complex protein(S) antigen from coronavirus.